艾司奥美拉唑联合伊托必利治疗胃食管反流性咽喉炎的疗效及安全性

Efficacy and safety of esomeprazole combined with itopride in the treatment of acid reflux disease laryngitis

目的探究胃食管反流性咽喉炎采取艾司奥美拉唑协同伊托必利诊疗的效果及安全性。方法选取2022年1月~2023年1月于我院就诊的胃食管反流性咽喉炎患者研究,合计78例,按随机抽样法分组,等比例分为对照组(给药艾司奥美拉唑)、治疗组(艾司奥美拉唑+伊托必利),比较2组指标,如治疗有效率、症状评分及安全性。结果①治疗有效率:治疗组治疗有效率97.44%,相较于对照组的高(P<0.05);②症状管理效果:基于反流症状指数、体征上,治疗组均较对照组低(P<0.05);③安全性:在腹泻、头痛等发生率方面(P>0.05);实验室指标:治疗后,与对照组比,治疗组ET-1、NO水平更低,GAS、MTL更高(P<0.05)。结论胃食管反流性咽喉炎采取艾司奥美拉唑协同伊托必利诊疗效果可观,有助于缓解症状,提高胃动力水平,安全性高,值得借鉴。

Objective To explore the efficacy and safety of esomeprazole combined with itopride in the diagnosis and treatment of acid reflux disease pharyngitis.Methods A total of 78 patients with acid reflux disease pharyngolaryngitis from January 2022 to January 2022 were randomly 2023,the patients were divided into control group(treated with esomeprazole)and treatment group(treated with esomeprazole and itopride)in equal proportion.The efficacy,symptom score and safety of the two groups were compared.Results 1 the effective rate of treatment:the effective rate of treatment group was 97.44%,which was higher than that of control group(p<0.05),2 the effect of symptom management:Based on the Index of reflux symptom and physical sign,the effective rate of treatment group was lower than that of control group(p<0.05);3 safety:in the incidence of diarrhea and headache(P>0.05),4 laboratory indexes:after treatment,the levels of ET-1 and NO in the treatment group were lower than those in the control group,and the levels of GAS and MTL were higher than those in the control group(p<0.05).Conclusion combined with itopride is effective in the diagnosis and treatment of acid reflux disease pharyngolaryngitis.It is helpful to relieve symptoms,improve gastric motility and is safe.